title: Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
abstract: OBJECTIVE
  To evaluate the use of raltegravir with unboosted atazanavir in combination with one nucleoside reverse transcriptase inhibitor (NRTI) (lamivudine or emtricitabine) as a potentially well-tolerated once-daily (qd) maintenance regimen.
  
  
  METHODS
  We compared the pharmacokinetics of raltegravir 400 mg twice daily (bid) with raltegravir 800 mg qd in HIV-infected patients (n=17) on unboosted atazanavir (600 mg qd) in combination with lamivudine or emtricitabine.
  
  
  RESULTS
  The area under the plasma concentration vs. time curve for a dose interval t (AUC0 -t ) of 800 mg qd divided by 2 was not significantly different from the AUC0 -t of 400 mg bid (P=0.664) but the minimum concentration (C min ) was 72% lower with the qd regimen (P=0.002). The regimen was well tolerated and the viral load remained undetectable in all patients during the 6 weeks of the study follow-up.
  
  
  CONCLUSIONS
  A qd regimen of raltegravir 800 mg, atazanavir 600 mg and lamivudine or emtricitabine resulted in favourable pharmacokinetic profiles and good short-term safety and efficacy data. Larger phase IIb studies are needed to explore this novel regimen.
authors.affiliation: Alysis Zorggroep, Arnhem, The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: Jansen
authors.forename: E P H
authors.initials: EP
authors.lastname: Colbers
authors.forename: A J A M
authors.initials: AJ
authors.lastname: van der Ven
authors.forename: C
authors.initials: C
authors.lastname: Richter
authors.forename: J K
authors.initials: JK
authors.lastname: Rockstroh
authors.forename: J C
authors.initials: JC
authors.lastname: Wasmuth
authors.forename: M
authors.initials: M
authors.lastname: van Luin
authors.forename: D M
authors.initials: DM
authors.lastname: Burger
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019562:Viral Load; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D009842:Oligopeptides; D011725:Pyridines; D011760:Pyrrolidinones; D018894:Reverse Transcriptase Inhibitors; D000068898:Raltegravir Potassium; D000069446:Atazanavir Sulfate
keywords: HIV integrase inhibitor; antiretroviral agents; atazanavir; drug interactions; pharmacokinetics; raltegravir